AIM: CDK4/6 inhibitors in the first and second treatment line in patients with HR+/HER2- metastatic breast cancer (mBC) in combination with hormonal therapy improve progression-free survival. Role of CDK4/6 inhibitors in further treatment lines remains unclear. METHODS: Retrospective analysis of 24 HR+/HER2- heavily pretreated mBC patients is presented. RESULTS: A total of 58.3% patients achieved stable disease. No objective response was observed. Median progression-free survival was 4.8 months; median overall survival was 11 months. Treatment was well tolerated. CONCLUSION: Favorable toxicity profile and efficacy of palbociclib/aromatase inhibitors combination in heavily pretreated luminal mBC patients in this study emphasize the need for further investigation of such drugs in this population.
AIM: CDK4/6 inhibitors in the first and second treatment line in patients with HR+/HER2- metastatic breast cancer (mBC) in combination with hormonal therapy improve progression-free survival. Role of CDK4/6 inhibitors in further treatment lines remains unclear. METHODS: Retrospective analysis of 24 HR+/HER2- heavily pretreated mBC patients is presented. RESULTS: A total of 58.3% patients achieved stable disease. No objective response was observed. Median progression-free survival was 4.8 months; median overall survival was 11 months. Treatment was well tolerated. CONCLUSION: Favorable toxicity profile and efficacy of palbociclib/aromatase inhibitors combination in heavily pretreated luminal mBC patients in this study emphasize the need for further investigation of such drugs in this population.
Authors: Luis Manso; Cristina Hernando; María Galán; Mafalda Oliveira; Miguel A Cabrera; Raquel Bratos; César A Rodríguez; Manuel Ruiz-Borrego; Salvador Blanch; Antonio Llombart-Cussac; Juan I Delgado-Mingorance; Iñaki Álvarez-Busto; Isabel Gallegos; Lucía González-Cortijo; Serafín Morales; Elena Aguirre; Blanca A Hernando; Ana Ballesteros; José E Alés-Martínez; Cristina Reboredo; Amparo Oltra; María González-Cao; Marta Santisteban; Diego Malón; Isabel Echeverría; Elisa García-Garre; Estela Vega; Sònia Servitja; Raquel Andrés; Carlos E Robles; Rafael López; Elena Galve; María J Echarri; Marta Legeren; Fernando Moreno Journal: Breast Date: 2020-11-13 Impact factor: 4.380